TWI923600B - 含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用 - Google Patents

含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用

Info

Publication number
TWI923600B
TWI923600B TW110126626A TW110126626A TWI923600B TW I923600 B TWI923600 B TW I923600B TW 110126626 A TW110126626 A TW 110126626A TW 110126626 A TW110126626 A TW 110126626A TW I923600 B TWI923600 B TW I923600B
Authority
TW
Taiwan
Prior art keywords
general formula
compound
compounds
iig
meso
Prior art date
Application number
TW110126626A
Other languages
English (en)
Chinese (zh)
Other versions
TW202214594A (zh
Inventor
楊方龍
賈敏強
陳剛
郭沛驊
張利敏
賀峰
陶維康
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海恆瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海恆瑞醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202214594A publication Critical patent/TW202214594A/zh
Application granted granted Critical
Publication of TWI923600B publication Critical patent/TWI923600B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
TW110126626A 2020-07-20 2021-07-20 含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用 TWI923600B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202010696995.5 2020-07-20
CN202010696995 2020-07-20
CN202010783483.2 2020-08-06
CN202010783483 2020-08-06
CN202011223930 2020-11-05
CN202011223930.5 2020-11-05
CN202110410441.9 2021-04-16
CN202110410441 2021-04-16

Publications (2)

Publication Number Publication Date
TW202214594A TW202214594A (zh) 2022-04-16
TWI923600B true TWI923600B (zh) 2026-05-01

Family

ID=79728998

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110126626A TWI923600B (zh) 2020-07-20 2021-07-20 含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用

Country Status (12)

Country Link
US (1) US20230257366A1 (enExample)
EP (1) EP4183781A4 (enExample)
JP (2) JP7863083B2 (enExample)
KR (1) KR20230042057A (enExample)
CN (3) CN120004860A (enExample)
AU (1) AU2021314401A1 (enExample)
BR (1) BR112023000817A2 (enExample)
CA (1) CA3184711A1 (enExample)
MX (1) MX2023000868A (enExample)
TW (1) TWI923600B (enExample)
WO (1) WO2022017365A1 (enExample)
ZA (1) ZA202301992B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116462660A (zh) * 2022-01-19 2023-07-21 江苏恒瑞医药股份有限公司 一种异喹啉酮类化合物的盐及其晶型
MX2024008959A (es) * 2022-01-19 2024-07-30 Jiangsu Hengrui Pharmaceuticals Co Ltd Forma cristalina de derivado de isoindolina que contiene azufre.
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
AU2024344247A1 (en) 2023-09-19 2026-05-07 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102822165A (zh) * 2010-02-11 2012-12-12 细胞基因公司 芳基甲氧基异吲哚啉衍生物和包括其的组合物及它们的使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CN101102771A (zh) 2004-11-23 2008-01-09 细胞基因公司 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物
CA2681633C (en) * 2007-03-20 2018-01-09 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
AU2017246452C1 (en) * 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
IL278854B2 (en) * 2018-05-23 2026-01-01 Celgene Corp Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
CA3121667A1 (en) 2018-09-30 2020-04-02 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoindoline compound, preparation method, pharmaceutical composition and use thereof
EP3908582B1 (en) * 2019-01-09 2025-11-12 Celgene Corporation Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
AU2020348849A1 (en) * 2019-09-19 2022-04-07 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
ES2988714T3 (es) * 2020-07-07 2024-11-21 Celgene Corp Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102822165A (zh) * 2010-02-11 2012-12-12 细胞基因公司 芳基甲氧基异吲哚啉衍生物和包括其的组合物及它们的使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 JD Hansen et al. Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma J. Med. Chem. 63 Mar.2020 6648-6676 *

Also Published As

Publication number Publication date
EP4183781A1 (en) 2023-05-24
AU2021314401A1 (en) 2023-03-09
JP7863083B2 (ja) 2026-05-20
JP2026094330A (ja) 2026-06-09
TW202214594A (zh) 2022-04-16
CA3184711A1 (en) 2022-01-27
CN120004859A (zh) 2025-05-16
MX2023000868A (es) 2023-02-22
CN115916768B (zh) 2024-12-24
KR20230042057A (ko) 2023-03-27
WO2022017365A1 (zh) 2022-01-27
JP2023534528A (ja) 2023-08-09
US20230257366A1 (en) 2023-08-17
ZA202301992B (en) 2026-05-27
BR112023000817A2 (pt) 2023-02-07
CN115916768A (zh) 2023-04-04
EP4183781A4 (en) 2024-01-03
CN120004860A (zh) 2025-05-16

Similar Documents

Publication Publication Date Title
CN115916768B (zh) 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
TW202144338A (zh) 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用
CN113980032A (zh) 稠合四环类衍生物、其制备方法及其在医药上的应用
CN113816948A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN113801114A (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN114805336A (zh) 稠合咪唑类化合物、其制备方法及其在医药上的应用
TWI914470B (zh) 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用
WO2022247816A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN114746414A (zh) 氮杂-喹啉化合物及其用途
TW202102505A (zh) 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用
CN113825757A (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
TW202106693A (zh) 吲哚類大環衍生物、其製備方法及其在醫藥上的應用
TW202045493A (zh) ２－胺基嘧啶類衍生物、其製備方法及其在醫藥上的應用
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN111205309B (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN114685429A (zh) 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用
CN115867552B (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
RU2847441C1 (ru) Серосодержащее производное изоиндолина, способ его получения и его медицинское применение
HK40090714B (en) Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof
HK40090714A (en) Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof
CN114456173B (zh) 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用
HK40064826A (en) Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines
CN119161325A (zh) 内酰胺类化合物、其制备方法及其在医药上的应用
CN118344348A (zh) 杂环取代喹唑啉及其制备方法和应用